US Patent No: 7,977,316
Number of patents in Portfolio can not be more than 2000
Prevention and treatment of amyloidogenic diseases
Stats
-
Jul 12, 2011
Issued date -
Aug 20, 2007
filing date -
11/842,046
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,441,870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein | 110 | 1992 | |
| 5,612,486 Transgenic animals harboring APP allele having swedish mutation | 129 | 1993 | |
| 6,114,133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) | 78 | 1994 | |
| 5,593,846 Methods for the detection of soluble .beta.-amyloid peptide | 192 | 1995 | |
| 5,605,811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein | 70 | 1995 | |
| 5,837,672 Methods and compositions for the detection of soluble .beta.-amyloid peptide | 99 | 1995 | |
| 6,284,221 Method for identifying .beta.-amyloid peptide production inhibitors | 59 | 1996 | |
|
|
|||
| 5,869,093 Treatment of immune diseases by oral administration of autoantigens | 58 | 1994 | |
| 5,645,820 Treatment of autoimmune diseases by aerosol administration of autoantigens | 55 | 1995 | |
| 5,571,499 Treatment of autoimmune diseases by aerosol administration of autoantigens | 67 | 1995 | |
| 5,571,500 Treatment of autoimmune diseases through administration by inhalation of autoantigens | 56 | 1995 | |
| 5,641,474 Prevention of autoimmune diseases by aerosol administration of autoantigens | 53 | 1995 | |
|
|
|||
| 5,849,298 Treatment of multiple sclerosis by oral administration of bovine myelin | 44 | 1993 | |
| 5,869,054 Treatment of multiple sclerosis by oral administration of autoantigens | 49 | 1995 | |
| 5,733,547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen | 47 | 1995 | |
| 5,641,473 Treatment of autoimmune diseases by aerosol administration of autoantigens | 47 | 1995 | |
|
|
|||
| 5,753,624 Materials and methods for treatment of plaquing disease | 72 | 1996 | |
| 5,851,996 Materials and methods for treatment of plaquing diseases | 77 | 1998 | |
| 6,294,171 Methods for treating disease states comprising administration of low levels of antibodies | 57 | 2001 | |
|
|
|||
| 5,837,473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue | 46 | 1995 | |
| 5,877,399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease | 107 | 1996 | |
| 6,262,335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 | 49 | 1998 | |
|
|
|||
| 5,220,013 DNA sequence useful for the detection of Alzheimer's disease | 64 | 1989 | |
| 5,187,153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives | 69 | 1990 | |
| 5,387,742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease | 178 | 1991 | |
|
|
|||
| 4,666,829 Polypeptide marker for Alzheimer's disease and its use for diagnosis | 235 | 1985 | |
| 5,270,165 Method of diagnosis of amyloidoses | 70 | 1991 | |
| 5,750,361 Formation and use of prion protein (PRP) complexes | 55 | 1995 | |
|
|
|||
| 5,057,540 Saponin adjuvant | 139 | 1990 | |
| 5,583,112 Saponin-antigen conjugates and the use thereof | 78 | 1992 | |
|
|
|||
| 5,750,349 Antibodies to .beta.-amyloids or their derivatives and use thereof | 109 | 1994 | |
| 5,955,317 Antibodies to .beta.-amyloids or their derivatives and use thereof | 72 | 1997 | |
|
|
|||
| 5,585,100 Dual carrier immunogenic construct | 65 | 1995 | |
| 5,955,079 Dual carrier immunogenic construct | 52 | 1995 | |
|
|
|||
| 5,622,701 Cross-reacting monoclonal antibodies specific for E- and P-selectin | 54 | 1994 | |
|
|
|||
| 5,935,927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts | 66 | 1996 | |
|
|
|||
| 5,972,369 Diffusional implantable delivery system | 48 | 1998 | |
|
|
|||
| 5,266,561 Treatment of type 2 diabetes mellitus | 20 | 1991 | |
|
|
|||
| 5,434,170 Method for treating neurocognitive disorders | 79 | 1993 | |
|
|
|||
| 5,786,180 Monoclonal antibody 369.2B specific for .beta. A4 peptide | 61 | 1995 | |
|
|
|||
| 5,643,562 Method for treating amyloidosis | 32 | 1995 | |
|
|
|||
| 2002/0136,718 Immunological control of beta-amyloid levels in vivo | 55 | 2001 | |
|
|
|||
| 5,679,348 Immunotherapy for recurrent HSV infections | 44 | 1992 | |
|
|
|||
| 5,824,322 Compositions and methods for growth promotion | 48 | 1996 | |
|
|
|||
| 5,231,170 Antibodies to dense microspheres | 66 | 1990 | |
|
|
|||
| 5,736,142 Alteration of immune response using pan DR-binding peptides | 66 | 1994 | |
|
|
|||
| 5,776,468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A | 62 | 1996 | |
|
|
|||
| 5,854,204 A.beta. peptides that modulate .beta.-amyloid aggregation | 94 | 1996 | |
|
|
|||
| 5,780,587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity | 64 | 1995 | |
|
|
|||
| 6,150,091 Direct molecular diagnosis of Friedreich ataxia | 46 | 1996 | |
|
|
|||
| 4,883,666 Controlled drug delivery system for treatment of neural disorders | 163 | 1987 | |
|
|
|||
| 6,057,367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses | 72 | 1997 | |
|
|
|||
| 5,773,007 Vaccine compositions | 20 | 1994 | |
|
|
|||
| 6,923,964 Active immunization of AScr for prion disorders | 24 | 2000 | |
|
|
|||
| 5,948,763 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits | 17 | 1996 | |
|
|
|||
| 5,866,124 Antiidiotypic antibodies for high molecular weight-melanoma associated antigen | 4 | 1996 | |
|
|
|||
| 5,004,697 Cationized antibodies for delivery through the blood-brain barrier | 74 | 1987 | |
|
|
|||
| 5,530,101 Humanized immunoglobulins | 607 | 1990 | |
|
|
|||
| 5,688,651 Prevention of protein aggregation | 80 | 1994 | |
|
|
|||
| 5,290,762 Treatment of inflammation | 21 | 1993 | |
|
|
|||
| 5,192,753 Anti-rheumatoid arthritic drugs in the treatment of dementia | 78 | 1991 | |
|
|
|||
| 5,208,036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor | 109 | 1990 | |
|
|
|||
| 5,972,269 Method of forming cavities in ceramic or metal injection molded parts using a fugitive core | 10 | 1997 | |
|
|
|||
| 5,854,996 Logic signal extraction | 27 | 1994 | |
|
|
|||
| 5,744,368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) | 55 | 1993 | |
|
|
|||
| 5,846,533 Antibodies specific for native PrP.sup.Sc | 67 | 1996 | |
|
|
|||
| 5,262,303 Ligand/anti-ligand assays for adherent proteins | 7 | 1990 | |
|
|
|||
| 6,417,178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits | 66 | 1997 | |
|
|
|||
| 5,231,000 Antibodies to A4 amyloid peptide | 95 | 1991 | |
|
|
|||
| 2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES | 33 | 1999 | |
|
|
|||
| 5,958,883 Animal models of human amyloidoses | 67 | 1995 | |
|
|
|||
| 5,989,566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation | 46 | 1996 | |
|
|
|||
| 2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease | 68 | 2001 | |
| 2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases | 57 | 2002 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Jan 12, 2015 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jan 12, 2019 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jan 12, 2023 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |